How bacterial carbohydrates influence the adaptive immune system

Annual Review of Immunology

Volumn 28, Issue , 2010, Pages 107-130

  Avci, Fikri Y ^a   Kasper, Dennis L ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Antigen presentation; Bacterial carbohydrates; Glycoconjugate vaccines; MHCII pathway; Zwitterionic polysaccharides

Indexed keywords

BACTERIAL CAPSULAR POLYSACCHARIDE; CARBOHYDRATE DERIVATIVE; GLYCOCONJUGATE VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; UNCLASSIFIED DRUG; VACCINE; BACTERIAL ANTIGEN; BACTERIAL POLYSACCHARIDE; BACTERIAL VACCINE;

ADAPTIVE IMMUNITY; B LYMPHOCYTE; CHEMICAL MODIFICATION; DRUG STRUCTURE; ENCAPSULATION; HUMAN; NONHUMAN; ORGANISMAL INTERACTION; PRIORITY JOURNAL; REVIEW; STREPTOCOCCUS AGALACTIAE; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; ANIMAL; BACTERIUM; CHEMISTRY; IMMUNOLOGY;

ADAPTIVE IMMUNITY; ANIMALS; ANTIGENS, BACTERIAL; BACTERIA; BACTERIAL VACCINES; HUMANS; POLYSACCHARIDES, BACTERIAL; T-LYMPHOCYTES;

EID: 77952303422     PISSN: 07320582     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev-immunol-030409-101159     Document Type: Review

References (74)

1. Hoagland CL, Beeson PB, Goebel WF. 1938. The capsular polysaccharide of the type XIV pneumococcus and its relationship to the specific substances of human blood. Science 88:261-263
2. Lindberg B, Lonngren J, Powell DA. 1977. Structural studies on the specific type-14 pneumococcal polysaccharide. Carbohydr. Res. 58:177-186
3. Weintraub A. 2003. Immunology of bacterial polysaccharide antigens. Carbohydr. Res. 338:2539-2547
4. Janeway CA, Travers P, Walport M, Chlomchik M. 2005. Immunobiology. New York: Garland Sci. 6th ed.
5. Edwards MS, Nicholson-Weller A, Baker CJ, Kasper DL. 1980. The role of specific antibody in alternative complement pathway-mediated opsonophagocytosis of Type III Group B Streptococcus. J. Exp. Med. 151:1275-1287
6. MacLeod CM, Hodges RG, Heidelberger M, Bernhard WG. 1945. Prevention of pneumococcal pneumonia by immunization with specific capsular polysaccharides. J. Exp. Med. 82:445-465
7. Lucas AH, Apicella MA, Taylor CE. 2005. Carbohydrate moieties as vaccine candidates. Clin. Infect. Dis. 41:705-712
8. Bhattacharjee AK, Jennings HJ, Kenny CP, Martin A, Smith IC. 1975. Structural determination of the sialic acid polysaccharide antigens of Neisseria meningitidis serogroups B and C with carbon 13 nuclear magnetic resonance. J. Biol. Chem. 250:1926-1932
9. Wessels MR, Paoletti LC, Rodewald AK, Michon F, DiFabio J, et al. 1993. Stimulation of protective antibodies against type Ia and Ib group B streptococci by a type Ia polysaccharide-tetanus toxoid conjugate vaccine. Infect. Immun. 61:4760-4766
10. Ovodov YS. 2006. Bacterial capsular antigens. Structural patternsofcapsular antigens. Biochemistry71:937-954
11. Tzianabos AO, Onderdonk AB, Rosner B, Cisneros RL, Kasper DL. 1993. Structural features of polysac-charides that induce intra-abdominal abscesses. Science 262:416-419
12. Cobb BA, Wang Q, Tzianabos AO, Kasper DL. 2004. Polysaccharide processing and presentation by the MHCII pathway. Cell 117:677-687
13. Duan J, Avci FA, Kasper DL. 2008. Microbial carbohydrate depolymerization by antigen-presenting cells: deamination prior to presentation by the MHCII pathway. Proc. Natl. Acad. Sci. USA 105:5183-5188
14. Wang Q, McLoughlin RM, Cobb BA, Charrel-Dennis M, Zaleksi KJ, et al. 2006. A bacterial carbohydrate links innate and adaptive responses through Toll-like receptor 2. J. Exp. Med. 203:2853-2863
15. Lesinski GB, Westerink MA. 2001. Vaccines against polysaccharide antigens. Curr. Drug Targets Infect. Disord. 1:325-334
16. Coutinho A, Moller G. 1973. B cell mitogenic properties of thymus-independent antigens. Nat. New Biol. 245:12-14
17. Coutinho A, Moller GJA, Bullock WW. 1973. In vitro activation of mouse lymphocytes in serum-free medium: effect of T and B cell mitogens on proliferation and antibody synthesis. Eur. J. Immunol. 3:299-306
18. McGhee JR, Michalek SM, Kiyono H, Eldridge JH, Colwell DE, et al. 1984. Mucosal immunoregula-tion: environmental lipopolysaccharide and GALT T lymphocytes regulate the IgA response. Microbiol. Immunol. 28:261-280
19. Barrett DJ. 1985. Human immune responses to polysaccharide antigens: an analysis of bacterial polysac-charide vaccines in infants. Adv. Pediatr. 32:139-158
20. Guttormsen H-K, Sharpe AH, Chandraker AK, Brigtsen AK, Sayegh MH, Kasper DL. 1999. Cognate stimulatory B-cell-T-cell interactions are critical for T-cell help recruited by glycoconjugate vaccines. Infect. Immun. 67:6375-6384
21. Mitchison NA. 1971. The carrier effectinthe secondary responsetohapten-protein conjugates. II. Cellular cooperation. Eur. J. Immunol. 1:18-25
22. Mitchison NA. 1971. The carrier effect in the secondary response to hapten-protein conjugates. I. Measurement of the effect with transferred cells and objections to the local environment hypothesis. Eur. J. Immunol. 1:10-17
23. Beuvery EC, Van Rossum F, Nagel J. 1982. Comparison of the induction of immunoglobulin M and G antibodies in mice with purified pneumococcal type III and meningococcal group C polysaccharides and their protein conjugates. Infect. Immun. 37:15-22
24. Schneerson R, Barrera O, Sutton A, Robbins JB. 1980. Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates. J. Exp. Med. 152:361-376
25. Trotter CL, McVernon J, Ramsay ME, Whitney CG, Mulholland EK, et al. 2008. Optimising the use of conjugate vaccines to prevent disease caused by Haemophilus influenzae type b, Neisseria meningitidis and Streptococcus pneumoniae. Vaccine 26:4434-4445
26. Jones C. 2005. NMR assays for carbohydrate-based vaccines. J. Pharm. Biomed. Anal. 38:840-850
27. Bardotti A, Averani G, Berti F, Berti S, Carinci V, et al. 2008. Physicochemical characterization of glycoconjugate vaccines for prevention of meningococcal diseases. Vaccine 26:2284-2296
28. Perez-Melgosa M, Ochs HD, Linsley PS, Laman JD, Meurs M, et al. 2001. Carrier-mediated enhancement of cognate T cell help: the basis for enhanced immunogenicity of meningococcal outer membrane protein polysaccharide conjugate vaccine. Eur. J. Immunol. 31:2373-2381
29. Peeters CC, Tenbergen-Meekes AM, Poolman JT, Beurret M, Zegers BJ, Rijkers GT. 1991. Effect of carrier priming on immunogenicity of saccharide-protein conjugate vaccines. Infect. Immun. 59:3504-3510
30. Pö llabauer EM, Petermann R, Ehrlich HJ. 2009. The influence of carrier protein on the immunogenicity of simultaneously administered conjugate vaccines in infants. Vaccine 27:1674-1679
31. H-cell peptide epitopes. Chemistry 19:5908-5917
32. Könen-Waisman S, Cohen A, Fridkin M, Cohen IR. 1999. Self heat-shock protein (hsp60) peptide serves in a conjugate vaccine against a lethal pneumococcal infection. J. Infect. Dis. 179:403-413
33. Wang JY, Chang AH, Guttormsen HK, Rosas AL, Kasper DL. 2003. Construction of designer glycocon-jugate vaccines with size-specific oligosaccharide antigens and site-controlled coupling. Vaccine 21:1112-1117
34. Amir-Kroll H, Riveron L, Sarmiento ME, Sierra G, Acosta A, Cohen IR. 2006. A conjugate vaccine composed of a heat shock protein 60 T-cell epitope peptide (p458) and Neisseria meningitidis type B capsular polysaccharide. Vaccine 24:6555-6563
35. Cohen N, Stolarsky-Bennun M, Amir-Kroll H, Margalit R, Nussbaum G, et al. 2008. Pneumococcal capsular polysaccharide is immunogenic when present on the surface of macrophages and dendritic cells: TLR4 signaling induced by a conjugate vaccine or by lipopolysaccharide is conducive. J. Immunol. 180:2409-2418
36. + T cell epitopes provide help to Haemophilus influenzae type b oligosaccharide: a model for new conjugate vaccines. Eur. J. Immunol. 31:3816-3824
37. Lai Z, Schreiber JR. 2009. Antigen processing of glycoconjugate vaccines; the polysaccharide portion of the pneumococcal CRM(197) conjugate vaccine colocalizes with MHC II on the antigen processing cell surface. Vaccine 27:3137-3144
38. Haurum JS, Arsequell G, Lellouch AC, Wong SYC, Dwek RA, et al. 1994. Recognition of carbohydrate by major histocompatibility complex class I-restricted, glycopeptide-specific cytotoxic T lymphocytes. J. Exp. Med. 180:739-744
39. Hanish F-G, Ninkovic T. 2006. Immunology of O-glycosylated proteins: approaches to the design of a MUC1 glycopeptide-based tumor vaccine. Curr. Protein Peptide Sci. 7:307-315
40. Werdelin O, Meldal M, Jensen T. 2002. Processing of glycans on glycoprotein and glycopeptide antigens in antigen-presenting cells. Proc. Natl. Acad. Sci. USA 99:9611-9613
41. Vlad AM, Muller S, Cudic M, Paulsen H, Otvos L, et al. 2002. Complex carbohydrates are not removed during processing of glycoproteins by dendritic cells: processing of tumor antigen MUC1 glycopeptides for presentation to major histocompatibility complex class II-restricted T cells. J. Exp. Med. 196:1435-1446
42. Dzhambazov B, Holmdahl M, Yamada H, Lu S, Vestberg M, et al. 2005. The major T cell epitope on type II collagen is glycosylated in normal cartilage but modified by arthritis in both rats and humans. Eur. J. Immunol. 35:357-366
43. Corthay A, Backlund J, Broddefalk J, Michaelsson E, Goldschmiddt T, et al. 1998. Epitope glycosylation plays a critical role for T cell recognition of type II collagen in collagen-induced arthritis. Eur. J. Immunol. 28:2580-2590
44. Brigl M, Brenner MB. 2004. CD1: antigen presentation and T cell function. Annu. Rev. Immunol. 22:817-890
45. Cobb BA, Kasper DL. 2005. Zwitterionic capsular polysaccharides: the new MHCII-dependent antigens. Cell. Microbiol. 7:1398-1403
46. Tzianabos AO, Wang JY, Lee JC. 2001. Structural rationale for the modulation of abscess formation by Staphylococcus aureus capsular polysaccharides. Proc. Natl. Acad. Sci. USA 98:9365-9370
47. McLoughlin RM, Lee JL, Kasper DL, Tzianabos AO. 2008. IFN-γ regulated chemokine production determines the outcome of Staphylococcus aureus Infection1. J. Immunol. 181:1323-1332
48. Velez CD, Lewis CJ, Kasper DL, Cobb BA. 2009. Type I Streptococcus pneumoniae carbohydrate utilizes a nitric oxide and MHC II-dependent pathway for antigen presentation. Immunology 127:73-82
49. Comstock LE, Kasper DL. 2006. Bacterial glycans: key mediators of diverse host immune responses. Cell 126:847-850
50. Krinos CM, Coyne MJ, Weinacht KG, Tzianabos AO, Kasper DL, Comstock LE. 2001. Extensive surface diversity of a commensal microorganism by multiple DNA inversions. Nature 414:555-558
51. Baumann H, Tzianabos AO, Brisson JR, Kasper DL, Jennings HJ. 1992. Structural elucidation of two capsular polysaccharides from one strain of Bacteroides fragilis using high-resolution NMR spectroscopy. Biochemistry 31:4081-4089
52. Wang JY, Kalka-Moll WM, Roehrl MH, Kasper DL. 2000. Structural basis of the abscess-modulating polysaccharide A2 from Bacteroides fragilis. Proc. Natl. Acad. Sci. USA 97:13478-13483
53. Choi YH, Roehrl MH, Kasper DL, Wang JY. 2002. A unique structural pattern sharedby T-cell-activating and abscess-regulating zwitterionic polysaccharides. Biochemistry 41:15144-15151
54. Kreisman LS, Friedman JH, Neaga A, Cobb BA. 2007. Structure and function relations with a T-cell-activating polysaccharide antigen using circular dichroism. Glycobiology 17:46-55
55. Cobb BA, Kasper DL. 2008. Characteristics of carbohydrate antigen binding to the presentation protein HLA-DR. Glycobiology 18:707
56. + T cells promote host memory immune responses to zwitterionic polysaccharide of Streptococcus pneumoniae. Infect. Immun. 77:3705-3712
57. Kalka-Moll WM, Tzianabos AO, Bryant PW, Niemeyer M, Ploegh HL, Kasper DL. 2002. Zwitteri-onic polysaccharides stimulate T cells by MHC class II-dependent interactions. J. Immunol. 169:6149-6153
58. van den Bosa LJ, Boltjea TJ, Provoosta T, Mazurekb J, Overkleefta HS, van der Marela GA. 2007. A synthetic study towards the PSA1 tetrasaccharide repeating unit. Tetrahedron Lett. 48:2697-2700
59. Mazmanian SK, Liu CH, Tzianabos AO, Kasper DL. 2005. Animmunomodulatory moleculeofsymbiotic bacteria directs maturation of the host immune system. Cell 122:107-118
60. Kolios G, Valatas V, Ward SG. 2004. Nitric oxide in inflammatory bowel disease: a universal messenger in an unsolved puzzle. Immunology 113:427-437
61. Vilar RE, Ghael D, Li M, Bhagat DD, Arrigo LM, et al. 1997. Nitric oxide degradation of heparin and heparan sulfate. Biochem. J. 324:473-479
62. Stingele F, Corthesy B, Kusy N, Porcelli SA, Kasper DL, Tzianabos AO. 2004. Zwitterionic polysaccha-rides stimulate T cells with no preferential Vβ usage and promote anergy, resulting in protection against experimental abscess formation. J. Immunol. 172:1483-1490
63. Gallorini S, Berti F, Parente P, Baronio R, Aprea S, et al. 2007. Introduction of zwitterionic motifs into bacterial polysaccharides generates TLR2 agonists able to activate APCs. J. Immunol. 179:8208-8215
64. Kasper DL, Onderdonk AB, Crabb J, Bartlett JG. 1979. Protective efficacy of immunization with capsular antigen against experimental infection with Bacteroides fragilis. J. Infect. Dis. 140:724-731
65. Onderdonk AB. 1979. Experimental animal models for anaerobic infections. Rev. Infect. Dis. 1:291-301
66. Tzianabos AO, Kasper DL, Cisneros RL, Smith RS, Onderdonk AB. 1995. Polysaccharide-mediated protection against abscess formation in experimental intra-abdominal sepsis. J. Clin. Invest. 96:2727-2731
67. Tzianabos AO, Onderdonk AB, Smith RS, Kasper DL. 1994. Structure-function relationships for polysaccharide-induced intra-abdominal abscesses. Infect. Immun. 62:3590-3593
68. Tzianabos AO, Russell PR, Onderdonk AB, GibsonFC 3rd, CywesC, et al. 1999. IL-2 mediates protection against abscess formation in an experimental model of sepsis. J. Immunol. 163:893-897
69. Tzianabos AO, Finberg RW, Wang Y, Chan M, Onderdonk AB, et al. 2000. T cells activated by zwit-terionic molecules prevent abscesses induced by pathogenic bacteria. J. Biol. Chem. 275:6733-6740
70. Mazmanian SK, Kasper DL. 2006. The love-hate relationship between bacterial polysaccharides and the host immune system. Nat. Rev. Immunol. 6:849-858
71. Ruiz-Perez B, Chung DR, Sharpe AH, Yagita H, Kalka-Moll W, et al. 2005. Modulation of surgical fibrosis by microbial zwitterionic polysaccharides. Proc. Natl. Acad. Sci. USA 102:16753-16758
72. Mazmanian SK, Round JL, Kasper DL. 2008. A microbial symbiosis factor prevents intestinal inflammatory disease. Nature 453:620-625
73. De Silva RA, Wang Q, Chidley T, Appulage DK, Andreana PR. 2009. Immunological response from an entirely carbohydrate antigen: design of synthetic vaccines based on Tn-PS A1 conjugates. J. Am. Chem. Soc. 131:9622-9623
74. Tzianabos AO, Wang JY, Kasper DL. 2003. Biological chemistry of immunomodulation by zwitterionic polysaccharides. Carbohydr. Res. 338:2531-2538